基于拓扑异构酶I(Topo I)/ DNA /喜树碱三元复合物的3D结构,设计并合成了含有环am,尿素或硫脲部分的新型六环喜树碱类似物。由9-硝基喜树碱经7,9-二氨基喜树碱衍生物作为关键中间体制备类似物。其中,7c在人类癌症异种移植模型中以最大耐受剂量表现出优于CPT-11的体内抗肿瘤活性,尽管其在体外的抗增殖活性可与SN-38媲美。
基于拓扑异构酶I(Topo I)/ DNA /喜树碱三元复合物的3D结构,设计并合成了含有环am,尿素或硫脲部分的新型六环喜树碱类似物。由9-硝基喜树碱经7,9-二氨基喜树碱衍生物作为关键中间体制备类似物。其中,7c在人类癌症异种移植模型中以最大耐受剂量表现出优于CPT-11的体内抗肿瘤活性,尽管其在体外的抗增殖活性可与SN-38媲美。
The present invention relates to hexacyclic compound of the formula [1],
1
wherein Z, R
3
and R
4
are as identified therein, and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of cell proliferative disorders.
Method for identifying an enzyme to design anti-cancer compounds
申请人:——
公开号:US20030138864A1
公开(公告)日:2003-07-24
The present invention relates to a method for identification of enzymes that are preferentially expressed in certain tumor tissue as compared with rapidly growing normal cells or tissue, use of said enzymes for the compound design to generate an active anti-cancer substance selectively in tumor tissue, compounds designed based on said enzymes, their pharmaceutically acceptable salts as well as pharmaceutical composition thereof.
The present invention relates to hexacyclic compound of the formula [1],
wherein Z, R3 and R4 are as identified therein, and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of cell proliferative disorders.
The present invention relates to hexacyclic compound of the formula [1],
wherein Z, R3 and R4 are as identified therein, and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of cell proliferative disorders.